Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2005

View Archived Issues

Targeting NPY-2 for genetic generalized epilepsies

Linolenic acid supplementation and ketogenic diet elicit comparable anticonvulsant effects in rats

Novel agents for treating neurological disorders disclosed in recent patent literature

Acetyl-CoA carboxylase inhibitors emerge from Ajinomoto R&D

Recent patents cover novel compounds with potential for treatment of cancer

Erbitux receives Swiss approval for head and neck cancer

Quest PharmaTech advances development of ACP-SL017

Neose Technologies updates NE-180 program

ANA-975 to begin phase Ib study in chronic hepatitis C patients

Introgen updates Advexin regulatory status

EntreMed to acquire Miikana Therapeutics

Fornix changes corporate structure and updates research programs

Ranbaxy and Cephalon settle Provigil patent infringement dispute in U.S.

Pennsaid confirmed effective in osteoarthritis of the knee

Bavarian Nordic updates program progress

Orencia approved for rheumatoid arthritis

Approvable letter for Daytrana

Astellas submits NDA for FK-506 modified release formulation

Plk1 inhibitors as tools to study cell division processes

Aricept orodispersible tablet completes Europe mutual recognition procedure

Adalimumab submitted for approval in Japan

New data on antibacterial activity of DX-619

Calcitonin effective, reduces biomarkers of joint metabolism in knee osteoarthritis

Oblimersen evaluated in myeloid and lymphocytic leukemia

Febuxostat may be superior to allopurinol in treating hyperuricemia and gout

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.